Publicación: Pre-Treatment Risk Assessment for Elderly Patients with Acute Myeloid Leukemia
dc.contributor.author | Arévalo Zambrano, Mónica | |
dc.contributor.author | Abello Polo, Virginia | |
dc.contributor.author | Omaña Orduz, Olga Paola | |
dc.contributor.author | Villamizar Gómez, Liceth | |
dc.date.accessioned | 2021-08-24T14:53:43Z | |
dc.date.available | 2021-08-24T14:53:43Z | |
dc.date.issued | 2018-09 | |
dc.description.abstract | The treatment of AML in older adults is limited by the high mortality related with induction chemotherapy; however, those who tolerate an intensive treatment will have better outcomes; therefore, selecting this group of patients through the use of functionality scales is a fundamental part of the initial therapeutic approach. Risk assessment scales have been designed and validated by other authors; in our country they have not been routinely used until now. Objective: To describe 8-week treatment related and 1- year mortality in AML patients, older than 60 years, after selecting treatment based on functionality risk scores (FRS), at two hospitals in Bogotá. Design: An observational study was performed, analyzing early mortality in two cohorts; a retrospective, including patients treated from 2010-2015 and a prospective one, from 2015 to 2018, in which the treatment was selected according FRS (SPPB, CCI and MD Anderson Predictive Score). Setting: Patients were treated in two university hospitals in Bogotá, Colombia. Patients: AML patients older than 60 years; acute promyelocytic leukemia patients were excluded. Interventions: FRS were assessed at diagnosis, high risk patients received supportive care, intermediate risk received 5-Azacitidine or low dose ARA-C, low risk patient wereconsidered eligible for standard induction chemotherapy (7+3). Main Outcomes Measures: We evaluated 8-week mortality as predicted by a combination of 3 different scales and compared it with a control retrospective cohort. Results: Sixty patients were included, median age 72 years (range: 62 - 84), 78% had intermediate cytogenetic risk and 20% high risk. 35% had a history of another hematological neoplasm. Only 38.3% received high intensity chemotherapy. Survival at 8 weeks was 70% without differences between treatment groups. One-year mortality was high, 73.9% of patients treated with 7x3 died, 80% in the low intensity group and 85.7% in the best support treatment. The ICC scale was predictive of 1-year mortality, but not the MD Anderson scale. Conclusions: In this high-risk group, 7+3 was well tolerated when patients were selected using FRS. The CCI scale was predictive of one-year mortality and could be used to optimize the selection of elderly patients with AML. | eng |
dc.format.extent | 2 p. | spa |
dc.format.mimetype | application/pdf | spa |
dc.identifier.uri | https://repositorio.fucsalud.edu.co/handle/001/1729 | |
dc.language.iso | eng | spa |
dc.publisher | Elsevier | spa |
dc.publisher.place | Estados Unidos | spa |
dc.relation.citationendpage | S206 | spa |
dc.relation.citationissue | 1 | spa |
dc.relation.citationstartpage | S205 | spa |
dc.relation.citationvolume | 18 | spa |
dc.relation.cites | Clinical lymphoma, myeloma and leukemia ISSN:2152-2650 Vol.18 Núm.1 (2018) | |
dc.relation.ispartofjournal | Clinical lymphoma, myeloma and leukemia | spa |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.rights.coar | http://purl.org/coar/access_right/c_abf2 | spa |
dc.rights.creativecommons | Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0) | spa |
dc.rights.uri | https://creativecommons.org/licenses/by-nd/4.0/ | spa |
dc.source | https://ur.booksc.eu/book/72643886/222f84 | spa |
dc.subject.decs | Trasplante de médula osea | |
dc.subject.decs | Azacitidina | |
dc.subject.decs | Síndromes mielodisplásicos | |
dc.subject.decs | Leucemia mieloide aguda | |
dc.subject.proposal | Acute myeloid leukemia | eng |
dc.subject.proposal | Myelodysplastic syndrome | eng |
dc.subject.proposal | Azacitidine | eng |
dc.subject.proposal | Bone marrow transplantation | eng |
dc.title | Pre-Treatment Risk Assessment for Elderly Patients with Acute Myeloid Leukemia | eng |
dc.type | Artículo de revista | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | spa |
dc.type.coarversion | http://purl.org/coar/version/c_970fb48d4fbd8a85 | spa |
dc.type.content | Text | spa |
dc.type.driver | info:eu-repo/semantics/article | spa |
dc.type.redcol | https://purl.org/redcol/resource_type/WP | spa |
dc.type.version | info:eu-repo/semantics/publishedVersion | spa |
dspace.entity.type | Publication |
Archivos
Bloque original
1 - 1 de 1
Cargando...
- Nombre:
- Pre-Treatment Risk Assessment for Elderly Patients with Acute Myeloid Leukemia.pdf
- Tamaño:
- 57.85 KB
- Formato:
- Adobe Portable Document Format
- Descripción:
- Artículo
Bloque de licencias
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- license.txt
- Tamaño:
- 15.06 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción: